Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
26
26 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- SEP-363856UlotarontPhase 37 trials
Otsuka · Generalized Anxiety Disorder, Schizophrenia, Major Depressive Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- HS-10380Phase 33 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · SCHIZOPHRENIA 1 (Disorder)
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- B2227Phase 31 trial
Bostal Drug Delivery Co., Ltd · Schizophrenia
- ML-007C-MAPhase 24 trials
MapLight Therapeutics · Psychosis Associated With Alzheimer's Disease, Schizophrenia
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
- BR5402APhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402A-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402BPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402B-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402CPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402C-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402DPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402D-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- GXV813Phase 21 trial
Novartis · Schizophrenia
- KYN-5356Phase 21 trial
Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)
- LY03020Phase 21 trial
Luye Pharma Group Ltd. · Schizophrenia
- NBI-1117570Phase 21 trial
Neurocrine Biosciences · Schizophrenia
- NS-136Phase 21 trial
NeuShen Therapeutics · Schizophrenia(Acute)
- RL-007InidascaminePhase 21 trial
Recognify Life Sciences · Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
- SIPI6398Phase 21 trial
Shanghai Zhongze Therapeutics Co., Ltd. · Schizophrenia Disorder
- VV119Phase 21 trial
Vigonvita Life Sciences · Schizophrenia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.